Biotech RadarJobs updated

COMPANY

Salubris Biotherapeutics

salubrisbio.com ↗

Clinical Phase 2

Profile checked Oct 10, 2026

Keywords: Heart Failure With Reduced Ejection Fraction Heart Failure With Preserved Ejection Fraction HFrEF - Heart Failure With Reduced Ejection Fraction HFpEF - Heart Failure With Preserved Ejection Fraction Melanoma Colorectal Cancer Non-small Cell Lung Cancer Small-cell Lung Cancer Urothelial Carcinoma Squamous Cell Carcinoma of Head and Neck Luminal Breast Cancer Triple Negative Breast Cancer Clear Cell Renal Cell Carcinoma Papillary Renal Cell Carcinoma Gastric Adenocarcinoma GastroEsophageal Cancer Squamous Cell Carcinoma Skin Pancreatic Adenocarcinoma Hepatocellular Carcinoma Colorectal Adenocarcinoma Epithelial Ovarian Cancer Thyroid Cancer JK07 JK06 JK08

6Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension source ↗
  2. Trial start Phase 1/Phase 2: Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer source ↗
  3. Trial start Phase 2: Study of JK07 in Patients With Chronic Heart Failure source ↗
  4. Trial start Phase 1: Single-Ascending Dose Study of JK07 in Subjects With HFpEF source ↗
  5. Trial start Phase 1/Phase 2: Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer source ↗
  6. Trial start Phase 1: Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 6

RecordTitlePhaseStatusStartPrimary completion
NCT06369298Study of JK07 in Patients With Chronic Heart FailurePhase 2Active, not recruitingMar 28, 2024Oct 31, 2026 (estimated)
NCT07221513Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary HypertensionPhase 2WithdrawnDec 15, 2025Apr 16, 2026 (actual)
NCT06667960Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic CancerPhase 1/Phase 2RecruitingOct 23, 2024Apr 1, 2028 (estimated)
NCT04210375Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)Phase 1CompletedSep 21, 2020Jun 8, 2023 (actual)
NCT05620134Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerPhase 1/Phase 2Active, not recruitingOct 17, 2022Oct 17, 2025 (estimated)
NCT05322616Single-Ascending Dose Study of JK07 in Subjects With HFpEFPhase 1WithdrawnOct 21, 2022May 26, 2023 (actual)
Feedback